Insider Transactions in Q1 2023 at Deciphera Pharmaceuticals, Inc. (DCPH)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$112,500
$15.57 P/Share
|
|
Feb 28
2023
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
2,427,693
+9.88%
|
$0
$0.01 P/Share
|
|
Feb 16
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,159
-2.51%
|
$17,385
$15.1 P/Share
|
|
Feb 16
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,370
-2.28%
|
$20,550
$15.1 P/Share
|
|
Feb 16
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,159
-1.95%
|
$17,385
$15.1 P/Share
|
|
Feb 16
2023
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,370
-2.28%
|
$20,550
$15.1 P/Share
|
|
Feb 16
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
971
-1.09%
|
$14,565
$15.1 P/Share
|
|
Feb 15
2023
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,151
+19.44%
|
-
|
|
Feb 15
2023
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,488
+21.51%
|
-
|
|
Feb 15
2023
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,151
+15.77%
|
-
|
|
Feb 15
2023
|
Daniel Lee Flynn Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,488
+21.5%
|
-
|
|
Feb 15
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,488
+15.61%
|
-
|
|
Feb 14
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
30,045
-80.02%
|
$480,720
$16.0 P/Share
|
|
Jan 24
2023
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,666,666
+7.79%
|
$29,999,988
$18.0 P/Share
|
|
Jan 17
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,403
-5.21%
|
$50,463
$21.24 P/Share
|
|
Jan 17
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,603
-3.21%
|
$33,663
$21.24 P/Share
|
|
Jan 17
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,403
-3.2%
|
$50,463
$21.24 P/Share
|
|
Jan 17
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,603
-4.37%
|
$33,663
$21.24 P/Share
|
|
Jan 17
2023
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,403
-5.21%
|
$50,463
$21.24 P/Share
|